 |
Contact Us Sitemap |
 |
|
 |
|
|
Latest Press Releases 2004 Press Releases 2003 Press Releases 2002 Press Releases 2001 Press Releases 2004 Annual Report Fact Sheet Contact |
 |
December 2004
December-27-2004
SciClone's ZADAXIN Added to Asian Pacific Consensus Recommendation for Treatment of Hepatitis B
December-23-2004
SciClone's European Partner Sigma-Tau Initiates Phase 3 ZADAXIN Hepatitis C Triple Therapy Trial; First Patients Enrolled and Receiving Treatment
November 2004
November-01-2004
SciClone Reports Third Quarter Results
November-01-2004
SciClone Announces Appointment of Richard J. Hawkins to Board of Directors
November-01-2004
SciClone's ZADAXIN Shows Promise in Triple Therapy Trial for Hepatitis C Non-Responder Patients; Endpoint Data Presented at World's Largest Meeting of Liver Specialists
October 2004
October-06-2004
SciClone To Report Third Quarter 2004 Results on November 1, 2004
October-04-2004
SciClone Announces ZADAXIN Poster to Be Presented at AASLD
September 2004
September-20-2004
SciClone Pharmaceuticals to Present at UBS Global Life Sciences Conference
August 2004
August-25-2004
Sciclone's Collaborative Partner Awarded U.S. Government Grant to Evaluate SCV-07
August-04-2004
SciClone Reports Second Quarter Results
July 2004
July-19-2004
SciClone to Report Second Quarter 2004 Results on August 4, 2004
July-14-2004
Donald R. 4Sellers Resigns as President and CEO of SciClone
June 2004
June-15-2004
SciClone's ZADAXIN Shows Promising Effects in Treating Brain Cancer in Animal Model Study
May 2004
May-26-2004
SciClone Announces Collaboration to Develop Pegylated ZADAXIN
May-24-2004
SciClone Phase 3 ZADAXIN Triple Therapy Hepatitis C Trial in Europe
May-20-2004
SciClone Achieves Enrollment Milestone For U.S. Phase-3 Hepititis-C Trials
May-14-2004
SciClone Pharmaceuticals to Present at UBS Specialty Pharmaceuticals Conference
April 2004
April-27-2004
SciClone to Report First Quarter 2004 Results on April 27, 2004
April-14-2004
SciClone Explores New Combination Therapy In Hepititis-B Clinical Trial
March 2004
March-01-2004
Sciclone’s Zadaxin Demonstrates Significant Anti-Fungal
Efficacy in Invasive Aspergillosis Animal Study
February 2004
February-24-2004
SciClone Reports Results for Fourth Quarter and Full Year 2003
February-18-2004
SciClone Reports Data: 41% of Hepititis-C Non-Responder Patients Test HCV RNA Negative After 24 Weeks of Zadaxin Triple Therapy
February-02-2004
SciClone to Report Fourth Quarter 2003 Results on February 24, 2004
Site design by Formative